Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Rhea-AI Summary

Serina Therapeutics (NYSE: SER) announces that its strategic partner and largest shareholder, Juvenescence Ltd., has secured $150 million in Series B funding led by M42, a tech-enabled health company from Abu Dhabi. The partnership includes plans to establish a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with advanced data and clinical infrastructure. Juvenescence's investment will support the development of innovative therapies targeting age-related diseases and extending healthspan. Serina Therapeutics, which is developing its POZ Platform drug optimization technology, benefits from Juvenescence's strategic guidance and capital support in advancing their clinical programs.

Insights

Biotechnology Investment Strategist

Juvenescence's $150M funding and M42 partnership creates strategic advantages for Serina through its major shareholder, enhancing drug development capabilities.

This funding round for Juvenescence represents a significant indirect positive for Serina Therapeutics, though the immediate financial impact on Serina itself requires careful assessment. As Juvenescence is described as Serina's largest shareholder and strategic partner, this $150 million capital infusion strengthens a key supporter of Serina's operations and development pipeline.

The strategic alliance between Juvenescence and M42 to establish a drug development hub in Abu Dhabi is particularly noteworthy. This creates potential synergistic opportunities for Serina's POZ Platform™ technology to benefit from enhanced AI-enabled drug discovery capabilities and access to M42's clinical infrastructure. For a clinical-stage biotech like Serina, having its major backer strengthen its financial position and expand its technological resources creates a more robust ecosystem for continued development.

The deal structure suggests Juvenescence is building a network of complementary biotechnology assets focused on age-related diseases, with Serina described as a "core portfolio company." This positioning within Juvenescence's strategic framework could lead to preferential access to resources, expertise, and potential development partnerships through the M42 connection. For investors in Serina, this relationship provides a degree of de-risking through association with better-capitalized partners while maintaining Serina's independent operational focus on its proprietary technology platform.

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, today congratulates its strategic partner and largest shareholder, Juvenescence Ltd., on securing $150 million in Series B financing led by M42, a global tech-enables health company headquartered in Abu Dhabi.

This significant investment and accompanying strategic alliance mark a major milestone in accelerating Juvenescence’s mission to develop innovative therapies targeting age-related diseases and extending healthspan. As part of this partnership, Juvenescence and M42 will launch a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with cutting-edge data and clinical infrastructure to speed the development of novel therapeutics.

“Juvenescence has been a critical partner to Serina, providing strategic guidance and capital that have helped us advance our POZ Platform^™ into the clinic,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “We congratulate Richard and the entire Juvenescence team on this next phase of growth and look forward to working together to deliver breakthrough treatments to patients around the world.”

“We are grateful for the continued support of our investors, including new investor and strategic partner M42, who have joined us on this remarkable journey. Our partnership with M42 signifies a shared commitment to developing sustainable, long-term collaborations,” said Dr. Richard Marshall CBE, CEO of Juvenescence. “Together, we are excited about the opportunity to help build a leading life-sciences hub in Abu Dhabi and establish a pipeline of innovative therapeutics that will improve the lives of millions of patients.”

As a core portfolio company of Juvenescence, Serina is proud to be part of a growing network of science-driven enterprises working to transform the future of medicine.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform^™provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

For more information, please visit https://serinatherapeutics.com.

About Juvenescence

Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases.

It was founded by Jim Mellon, Dr Greg Bailey, and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totaling $30bn in peak annual sales.

Powered by an unrivaled drug development team, Juvenescence leverages innovative AI tools to unlock successful therapeutics. The company’s diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity, and cellular repair. In addition, Juvenescence has investments in a number of innovative companies and platform technologies focused on AI and regenerative medicine. 

For more information, visit: www.JuvLabs.com

About M42

M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive, and predictive care, impactfully disrupt traditional healthcare models and positively impact lives globally.

Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Program, M42 runs Abu Dhabi BioBank and ADHDS, a global tech-enabled healthcare company operating Malaffi.

For inquiries, please contact:
Stefan Riley 
sriley@serinatherapeutics.com
(256) 327-9630

FAQ

What is the size of Juvenescence's Series B funding round that impacts Serina Therapeutics (SER)?

Juvenescence Ltd. secured $150 million in Series B funding led by M42, a tech-enabled health company from Abu Dhabi.

How is Serina Therapeutics (SER) connected to Juvenescence Ltd.?

Juvenescence Ltd. is Serina Therapeutics' strategic partner and largest shareholder, providing strategic guidance and capital support for advancing their POZ Platform technology.

What is the purpose of the M42 and Juvenescence partnership in Abu Dhabi?

The partnership aims to establish a drug development hub in Abu Dhabi that combines AI-enabled drug discovery with advanced data and clinical infrastructure to accelerate therapeutic development.

What technology is Serina Therapeutics (SER) developing?

Serina Therapeutics is developing its proprietary POZ Platform drug optimization technology, currently in the clinical stage.

Who is the CEO of Serina Therapeutics (SER)?

Steve Ledger is the Chief Executive Officer of Serina Therapeutics.